Hepatic Encephalopathy clinical trials at University of California Health
3 in progress, 2 open to eligible people
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
open to eligible people ages 18 years and up
This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.
at UCSF
Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
open to eligible people ages 18 years and up
The purpose of the study is to evaluate the safety of Rifaximin or placebo in subjects with severe hepatic impairment and Hepatic Encephalopathy.
at UCSD
TReatment for ImmUne Mediated PathopHysiology
Sorry, not currently recruiting here
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
at UCSF
Our lead scientists for Hepatic Encephalopathy research studies include Michael Mendler, MD.
Last updated: